



For Immediate Release

May 31, 2006

Company Name: Dainippon Sumitomo Pharma Co., Ltd.

President: Kenjiro Miyatake

Stock Exchange Listings: Tokyo, Osaka, Nagoya

Security Code number: 4506

**Dainippon Sumitomo Pharma and Chelsea Therapeutics International Signed
Licensing Agreement for Dops[®] for the treatment of orthostatic hypotension.**

Dainippon Sumitomo Pharma Co., Ltd. (DSP) today announced that it has licensed the rights to Dops[®] (L-threo-Dops, droxidopa, norepinephrine-induced adrenergic neurofunction improving agent) to Chelsea Therapeutics International, Ltd. (Chelsea; NASDAQ:CHTP).

Under this agreement, DSP grants exclusive development and commercialization rights of Dops[®] to Chelsea worldwide excluding Japan, Korea, China and Taiwan.

Dops[®], a precursor of norepinephrine (NE), is converted to NE thereby improving symptoms related to NE deficiency. Dops[®] initially received approval in 1989 for the treatment of frozen gait or dizziness associated with Parkinson's Disease and others in Japan. In 2000, DSP received expanded marketing approval to include treatment of vertigo, dizziness and weakness associated with orthostatic hypotension in hemodialysis patients.

With the agreement announcement today, Chelsea will begin clinical development of Dops[®] for the treatment of neurogenic orthostatic hypotension with Orphan Drug Status.

DSP is looking forward to further contributions to global healthcare as the result of obtaining an approval of Dops[®] for the treatment of orthostatic hypotension.

About Chelsea Therapeutics International, Ltd.

Name: Chelsea Therapeutics International, Ltd.

Date of Establishment: 2002

Head Office: 13950 Ballantyne Corp. Place Suite 325 Charlotte, NC 28277

President and CEO: Dr. Simon Pedder (President and CEO)

Businesses: Chelsea concentrates its efforts on acquiring and developing technologies for the treatment of rheumatoid arthritis (RA), psoriasis, cancer and other immunological disorders.

URL <http://www.chelseatherapeutics.com/>